Are we focused on the wrong risk type in genetic screening? Breast cancer screening study shows new paths to population screening

“Father of tamoxifen” V. Craig Jordan dies at 76

Pharmacologist V. Craig Jordan, a professor of Breast and Medical Oncology and Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center who discovered selective estrogen receptor modulators and developed breakthrough breast cancer treatments, died June 9 at his home in Houston.

June 14, 2024

Vol.50 No.24

By MD Anderson Cancer Center staff

In the Archives

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

V. Craig Jordan, a pharmacologist who discovered selective estrogen receptor modulators, died on June 9. Jordan, a professor at The University of Texas MD Anderson Cancer Center who was credited with discovery of tamoxifen, was 76. An obituary appears in this issue. Jordan appeared on the Cancer History Project podcast in 2022 to discuss...

June 14, 2024

Vol.50 No.24

Clinical Roundup

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Fewer than one in five eligible individuals in the United States are up-to-date with recommended lung cancer screening, according to a study led by American Cancer Society researchers.

June 14, 2024

Vol.50 No.24

Clinical Roundup

Hydroxychloroquine + lapatinib may reduce breast cancer metastases

A study led by researchers from the University of Arizona Cancer Center at UArizona Health Sciences identified a biological mechanism that could lead to more effective treatments for breast cancer that has metastasized to the brain. The work was published in Clinical and Translational Medicine.

June 14, 2024

Vol.50 No.24

Clinical Trials & Tribulations

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

In May, the American Society of Clinical Oncology released guidelines on the use of germline genetic testing panels in concert with tumor testing for cancer patients. xxx:more

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

Dennis Slamon, an oncologist and scientist whose research has transformed the treatment of breast cancer, was awarded the 2024 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

June 07, 2024

Vol.50 No.23

Are we focused on the wrong risk type in genetic screening?

Breast cancer screening study shows new paths to population screening

YOU MAY BE INTERESTED IN

“Father of tamoxifen” V. Craig Jordan dies at 76

In an interview and a memoir, V. Craig Jordan spoke about his life and SERMs

Fewer than 20% of U.S. adults eligible for lung cancer screening comply with USPSTF guideline

Hydroxychloroquine + lapatinib may reduce breast cancer metastases

Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists

Dennis Slamon receives Szent-Györgyi Prize from National Foundation for Cancer Research

Renew today!

Subscriber content

Login